

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



12/693,712 09/08/00

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18		A2	(12) International Publication Number: WO 97/17086
			(43) International Publication Date: 15 May 1997 (15.05.97)
(21) International Application Number: PCT/JP96/03277		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 8 November 1996 (08.11.96)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 7/291238 9 November 1995 (09.11.95) JP			
(71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).			
(72) Inventor; and (75) Inventor/Applicant (for US only): KOJIMA, Itaru [JP/JP]; 1-7-301, Bunkyocho 1-chome, Maebashi-shi, Gunma 371 (JP).			
(74) Agents: ASAHINA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).			
(54) Title: COMPOSITION FOR IMPROVING PANCREATIC FUNCTION			
(57) Abstract			
<p>The present invention provides an excellent composition for improving pancreatic function, the composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells and the composition for preventing or treating undifferentiated type of pancreatic cancer, which comprises a BTC protein or a mutein thereof. The composition of the present invention acts on undifferentiated pancreatic stem cells to promote their differentiation to insulin-producing pancreatic beta cells. It also has an activity for induction of differentiation of undifferentiated pancreatic stem cells to other pancreatic cells such as F cells which produce pancreatic peptides. The composition of the present invention is therefore capable of promoting mitigation and healing of diabetes mellitus (e.g., insulin-dependent diabetes mellitus), pancreatic dysfunction in diabetes mellitus etc., and improves pancreatic function. And, the composition of the present invention is also useful as a composition for preventing or treating undifferentiated type of pancreatic cancer.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTION

COMPOSITION FOR IMPROVING PANCREATIC FUNCTION

5

Technical Field

The present invention relates to a composition for improving pancreatic function, a composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells, or a composition for preventing or treating undifferentiated pancreatic cancer, which comprises a betacellulin protein or a mutein thereof.

15 Background Art

A betacellulin protein (hereinafter also referred to as BTC protein) is a peptide factor produced by pancreatic beta tumor cells derived from a transgenic mouse, and its full amino acid sequence has been clarified by cDNA analysis [Shing et al., Science, 259:1604 (1993); Sasada et al., Biochemical and Biophysical Research Communications, 190: 1173 (1993)]. Although BTC protein was first discovered as a factor possessing mouse 3T3 cell growth-promoting activity, it was later found to exhibit growth-promoting activity against vascular smooth muscle cells and retinal pigment epithelial cells [Shing et al., Science, 259:1604 (1993)].

A human BTC protein naturally occurs in very trace amounts, and attempts to obtain it from human tissue has been very difficult by various limitations. In recent years, however, gene engineering techniques have been successfully used to produce highly purified human BTC protein in large amounts and at relatively low costs (EP-A-0555785). Also, it has been reported that BTC protein can be used in the treatment of diseases such as wounds, tumors

and vascular malformations, and preparation of competitive agents such as antibodies or false peptides which can be used in the treatment of such diseases attributable to smooth muscle growth as atherosclerosis and diabetic
5 retinopathy (EP-A-0482623, EP-A-0555785).

In addition, the mRNA of BTC protein has been detected in non-brain organs, e.g., liver, kidney and pancreas, suggesting that BTC protein exhibits some function in these organs as well, but much remains to be known in detail.

10

Disclosure of Invention

Diabetes mellitus is a disease characterized by the onset of various complications associated with persistent hyperglycemia. This disease is classified into insulin-
15 dependent, insulin-independent and other types, and is thought to be associated with diverse causes, but basically it develops when insulin action is diminished. Insulin-dependent diabetes mellitus, in particular, is caused by an absolute lack of insulin production. Against this back-
20 ground is there a need for the development of a medicine which improves pancreatic function to prevent or treat diabetes mellitus etc.

In view of the above problems, the present inventors made extensive investigation and found that known BTC
25 protein acts on cells derived from the pars exocrina pancreatis capable of multiple differentiation to allow them to differentiate to beta cells etc.. The present inventors made further investigation based on this finding, and developed the present invention.

30 Accordingly, the present invention provides:
(1) A composition for improving pancreatic function which comprises a betacellulin protein or a mutein thereof;
(2) The composition according to (1), wherein the betacellulin protein is a protein having the amino acid
35 sequence shown by at least one SEQ ID NO. selected from the

group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;

(3) The composition according to (1), wherein the betacellulin protein is a protein having the amino acid sequence shown by SEQ ID NO:1 or a protein having the amino acid sequence shown by SEQ ID NO:2;

(4) The composition according to (1), wherein the mutein of the betacellulin protein is a protein having (i) an amino acid sequence resulting from deletion of about 1 to 40 amino acids from the amino acid sequence shown by SEQ ID NO:1 or SEQ ID NO:2, (ii) an amino acid sequence resulting from replacement of about 1 to 40 amino acids in the amino acid sequence shown by SEQ ID NO:1 or SEQ ID NO:2 by other amino acid sequences, or (iii) an amino acid sequence resulting from addition of about 1 to 40 amino acids to the amino acid sequence shown by SEQ ID NO:1 or SEQ ID NO:2;

(5) The composition according to (1), wherein the mutein of the betacellulin protein is a protein having an amino acid sequence resulting from deletion of 12 or 30 amino acids from the N-terminus of the amino acid sequence shown by SEQ ID NO:1;

(6) The composition according to (1) to (5), which further contains an activin;

(7) The composition according to (6), wherein the content ratio of the activin to the betacellulin protein or a mutein thereof is about 1:10 to 10:1;

(8) The composition according to (1) to (7), which is a composition for preventing or treating diabetes mellitus.

(9) The composition according to (1) to (7), which is a composition for preventing or treating pancreatic dysfunction in diabetes mellitus or pancreatic hypofunction associated with senile insulin secretion reduction;

(10) A composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells, which comprises a betacellulin protein or a mutein thereof;

- (11) A composition for preventing or treating undifferentiated type of pancreatic cancer, which comprises a betacellulin protein or a mutein thereof;
- 5 (12) A method for improving pancreatic function of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal;
- 10 (13) A method for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal;
- 15 (14) A method for preventing or treating undifferentiated type of pancreatic cancer of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal;
- 20 (15) A use of a betacellulin protein or a mutein thereof for the manufacture of a composition for improving pancreatic function;
- (16) A use of a betacellulin protein or a mutein thereof for the manufacture of a composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells;
- 25 (17) A use of a betacellulin protein or a mutein thereof for the manufacture of a composition for preventing or treating undifferentiated pancreatic cancer.

Also, the present invention further provides:

- 30 (18) A composition for improving pancreatic function which comprises a DNA coding for a betacellulin protein or a mutein thereof;
- (19) A composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells, which comprises a DNA coding for a betacellulin protein or a mutein thereof;
- 35

(20) A composition for preventing or treating undifferentiated pancreatic cancer, which comprises a DNA coding for a betacellulin protein or a mutein thereof;

5 (21) A method for improving pancreatic function of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal;

10 (22) A method for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal;

(23) A method for preventing or treating undifferentiated pancreatic cancer;

15 (24) A use of a DNA coding for a betacellulin protein or a mutein thereof for the manufacture of a composition for improving pancreatic function;

20 (25) A use of a DNA coding for a betacellulin protein or a mutein thereof for the manufacture of a composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells; and

25 (26) A use of a DNA coding for a betacellulin protein or a mutein thereof for the manufacture of a composition for preventing or treating undifferentiated type of pancreatic cancer.

Brief Description of the Drawings

Figure 1 shows betacellulin protein concentration dependency of differentiation to insulin-producing beta cells or differentiation to pancreatic polypeptide (PP)-producing F cells. The abscissa indicates betacellulin protein concentration (M) and the ordinate indicates the ratio (%) of hormone-producing cells to the total cells. ○ indicates the number of insulin-producing beta cells and ● indicates the number of PP-producing cells.

30

35

Figure 2 shows the effects of various factors on differentiation to insulin-producing beta cells. The ordinate indicates factor designations of factors and the abscissa indicates the ratio (%) of insulin-producing cells to the total cells. EGF indicates epithelial growth factor; TGF- α indicates transforming growth factor α ; Betacellulin indicates human betacellulin protein. The concentration of Activin A, EGF, TGF- α and betacellulin is 1×10^{-19} M, respectively. Activin A + EGF, Activin A + TGF- α and Activin A + Betacellulin indicate the combination of 1×10^{-19} M of EGF, TGF- α or betacellulin with 2×10^{-19} M of Activin A, respectively.

Figure 3 shows insulin secretion from AR42J cells which have differentiated to insulin-producing beta cells in the presence of potassium ions or tolbutamide. None, high K and tolbutamide on the abscissa indicate the absence of potassium ions and tolbutamide, presence of 40 mM potassium, and 10 μ M tolbutamide, respectively. The ordinate indicates secreted insulin concentration (pg/mg-protein).

Figure 4 shows the glucose tolerance-improving activity of human betacellulin protein in diabetic mice in case of intraperitoneal glucose tolerance test (ipGTT) after 0 week before alloxan treatment. The abscissa indicates the time after administering glucose to intraperitoneal. The ordinate indicates blood glucose levels (mg/ml). \circ , \bullet and \blacktriangle show the result of alloxan non-treated mouse, alloxan treated/human betacellulin non-administered mouse and alloxan treated/human betacellulin administered mouse, respectively.

Figure 5 shows the glucose tolerance-improving activity of human betacellulin protein in diabetic mice in case of intraperitoneal glucose tolerance test (ipGTT) 4 weeks after alloxan treatment. The abscissa indicates the time after administering glucose to intraperitoneal. The ordinate indicates blood glucose levels (mg/ml). \circ , \bullet and

▲ show the result of alloxan non-treated mouse, alloxan treated/human betacellulin non-administered mouse and alloxan treated/human betacellulin administered mouse, respectively.

5 Figure 6 shows the glucose tolerance-improving activity of human betacellulin protein in diabetic mice in case of intraperitoneal glucose tolerance test (ipGTT) 8 weeks after alloxan treatment. The abscissa indicates the time after administering glucose to intraperitoneal. The
10 ordinate indicates blood glucose levels (mg/ml). ○, ● and ▲ show the result of alloxan non-treated mouse, alloxan treated/human betacellulin non-administered mouse and alloxan treated/human betacellulin administered mouse, respectively.

15 Figure 7 shows the growth-inhibiting activity of human betacellulin protein against pancreatic cancer cells. The abscissa indicates the culture days. The ordinate indicates the number ($\times 10^{-3}$) of No. 71 clone cells of AR42J cells derived from pancreatic cancer. ○ indicates the
20 result of incubation on human BTC protein-containing medium. ● indicates the result of incubation on non-human BTC protein-containing medium.

As BTC protein which can be used for the composition for improving pancreatic function (hereinafter also referred to as composition for improving), the composition
25 for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells (hereinafter also referred to as composition for promoting) or the composition for preventing or treating undifferentiated
30 type of pancreatic cancer (hereinafter also referred to as composition for preventing or treating undifferentiated type of pancreatic cancer) of the present invention, which comprise BTC protein or a mutein thereof as long as it has BTC-like activity, i.e., growth-promoting activity on
35 fibroblasts, vascular smooth muscle cells, retinal pigment epithelial cells and other cells, any BTC protein can be

used. And, non-protein substances, e.g., fermentation products, synthetic compounds and synthetic peptides, can also be used. The BTC protein may be of natural origin, or may be a recombinant protein produced by a gene engineering technique.

As BTC protein of natural origin BTC protein, may be derived from any animal, such as humans, monkeys, hamadryad baboons, chimpanzees, pigs, bovines, sheep, horses, mice and rats. Preferable BTC proteins include those of human or mouse origin, those of human origin are more preferable. It is also preferable to use a BTC protein derived from the same animal species as the animal subject to which the composition for improving, the composition for promoting or the composition for preventing or treating of the present invention is applied. When the composition for improving and so on of the present invention is applied to humans, it is preferable to use BTC protein of human origin.

Examples of BTC proteins are a protein having an amino acid sequence shown by at least one SEQ ID NO. selected from the group consisting of SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6, and so on.

Preferable examples of BTC proteins of human origin are a protein having the amino acid sequence shown by SEQ ID NO:1 (EP-A-0555785) and so on. Examples of BTC proteins of mouse origin are a protein having the amino acid sequence shown by SEQ ID NO:2 [Shing et al., Science, 259:1604 (1993)] and so on.

These BTC proteins may be simple proteins configured with amino acids only, or complex proteins such as glycoproteins, lipoproteins, heme proteins, metal proteins, flavin proteins and phosphoproteins. When the BTC protein is a glycoprotein, examples of its sugar chains are neutral sugars such as D-mannose, D-galactose and L-fructose, amino sugars such as D-glucosamine and D-galactosamine, and sialic acid.

Examples of muteins of BTC protein are deletion-type muteins resulting from deletion of at least one constituent amino acids of the above-described BTC protein, replacement-type muteins resulting from replacement of at least one constituent amino acid of the BTC protein by other amino acids, and addition-type muteins resulting from addition of at least one amino acids to the BTC protein. The number of amino acid deletions, replacements or additions may be any one, as long as the BTC protein retains its essential activity.

Preferable examples of muteins of BTC protein are proteins having (i) an amino acid sequence resulting from deletion of about 1 to 40 amino acids from the amino acid sequence represented by SEQ ID NO:1 or SEQ ID NO:2, (ii) an amino acid sequence resulting from replacement of about 1 to 40 amino acids in the amino acid sequence represented by SEQ ID NO:1 or SEQ ID NO:2 by other amino acid sequences, or (iii) an amino acid sequence resulting from addition of about 1 to 40 amino acids to the amino acid sequence represented by SEQ ID NO:1 or SEQ ID NO:2, and more preferable examples of muteins of BTC protein are proteins having at least one of the following partial amino acid sequences:

- 1) His Phe Ser Arg Cys Pro Lys Gln Tyr Lys His Tyr Cys Ile (SEQ ID NO:3),
- 2) Gly Arg Cys Arg Phe Val Val (SEQ ID NO:4),
- 3) Glu Gln Thr Pro Ser Cys (SEQ ID NO:5), and
- 4) Gly Ala Arg Cys Glu Arg Val Asp Leu Phe Tyr (SEQ ID NO:6).

Of these muteins, deletion-type muteins etc. are preferred, and proteins having an amino acid sequence resulting from deletion of about 1 to 40 amino acids from the N-terminus of the amino acid sequence represented by SEQ ID NO:1 or SEQ ID NO:2 are more preferable. More specifically, preferable examples of deletion-type muteins of BTC protein are deletion-type muteins of human or mouse

BTC protein having an amino acid sequence resulting from deletion of 12 or 30 amino acids from the N-terminus of the amino acid sequence represented by SEQ ID NO:1 or SEQ ID NO:2 [Watanabe et al., Journal of Biochemistry, 269:9966 (1994)]. More preferable examples of deletion-type muteins are deletion-type muteins of human BTC protein having an amino acid sequence resulting from 12 or 30 amino acids from the N-terminus of the amino acid sequence represented by SEQ ID NO:1.

As any other BTC protein mutein, as long as the activity of the BTC protein is retained, any proteins such as muteins resulting from acylation of the N-terminus of BTC protein, those resulting from glycosylation, and those resulting from chemical modification such as polyethylene glycol derivatives are used.

Of the BTC proteins or muteins thereof used for the composition for improving, the composition for promoting or the composition for preventing or treating undifferentiated type of pancreatic cancer of the present invention, the human BTC protein having the amino acid sequence represented by SEQ ID NO:1, deletion-type human BTC muteins having an amino acid sequence resulting from deletion of 12 or 30 amino acids from the N-terminus of the amino acid sequence represented by SEQ ID NO:1, and mouse BTC proteins having the amino acid sequence represented by SEQ ID NO:2 are known; and the other BTC proteins and muteins thereof can be produced by known methods or modifications based thereon.

Also, the C-terminal carboxyl group of the BTC proteins or muteins thereof can be an amide ($-\text{CONH}_2$) or an ester thereof.

The salt of said BTC protein or a mutein thereof of the present invention includes preferably pharmaceutically acceptable acid addition salts. Examples of such salts are salts thereof with inorganic acids (e.g. hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.),

salts thereof with organic acids (e.g. acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.), etc.

BTC proteins may be manufactured by synthesizing methods for peptides which are known per se by those skilled in the art or methods similar thereto or by cleaving (digesting) BTC protein of the present invention or a precursor thereof by a suitable peptidase. Methods of synthesizing peptide may be any of a solid phase synthesis and a liquid phase synthesis. Thus, a partial peptide or amino acids which can construct the protein of the present invention or a precursor thereof is condensed with the residual part thereof and, when the product has a protective group, said protective group is detached whereupon a desired peptide can be manufactured. Examples of the known methods for condensation and for detachment of protective groups include the following ① to ⑤:

- ① M. Bodanszky and M. A. Ondetti: Peptide Synthesis, Interscience Publishers, New York (1966).
- ② Schroeder and Luebke: The Peptide, Academic Press, New York, 1965.
- ③ Nobuo Izumiya et al.: Fundamentals and Experiments of the Peptide Synthesis, Maruzen KK, Japan (1975).
- ④ Haruaki Yajima and Shumpei Sakakibara: "Seikagaku Jikken Koza 1" (Experiments of Biochemistry, Part 1), "Tanpakusitu No Kagaku IV" (Chemistry of Protein, IV), p.205 (1977), Japan.
- ⑤ Haruaki Yajima (ed): Development of Pharmaceuticals (Second Series), Vol. 14, Peptide Synthesis, Hirokawa Shoten, Japan.

After the reaction, conventional purifying techniques such as salting-out, extraction with solvents, distillation, column chromatography, liquid chromatography,

electrophoresis, recrystallization, etc. are optionally combined so that the protein of the present invention or a precursor thereof can be purified and isolated. When the protein obtained as such is a free compound, it may be converted to a suitable salt by known methods while, when it is obtained as a salt, the salt may be converted to a free compound or other salt compounds by known methods.

In addition to the above-described BTC protein or a mutein thereof, the composition for improving, the composition for promoting and the composition for preventing or treating undifferentiated type of pancreatic cancer of the present invention may comprise activin.

Activin is known as a hormone that promotes follicle-stimulating hormone secretion (Jikken Igaku, Vol. 10, No. 15, 1992). Examples of activin are activin A, activin B and activin AB, and preferable examples are activin A and so on. These activins may be commercial products (Austral Biological).

Because activin enhances BTC protein's activity, though it does not have BTC protein's activity, it is preferable to use it with BTC protein.

Also, activin is preferably used as formulated in the composition for improving and so on of the present invention. However it may be prepared separately from BTC protein to enable combined use of a composition comprising the BTC protein and a composition comprising activin in order to enhance BTC protein action.

As a DNA coding for BTC protein or a mutein thereof which can be used for the composition for improving pancreatic function (hereinafter also referred to as DNA-containing composition for improving), the composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells (hereinafter also referred to as DNA-containing composition for promoting) or composition for preventing or treating undifferentiated type of pancreatic cancer (hereinafter also referred to as

DNA-containing composition for preventing or treating undifferentiated type of pancreatic cancer) of the present invention, which comprise a DNA coding for BTC protein or a mutein thereof, any DNAs coding for the above mentioned BTC protein or a mutein thereof can be used.

The DNAs may be any one of a genome DNA, a genome DNA library, a tissue and cell-derived cDNA, a tissue and cell-derived cDNA library and a synthetic DNA. The vector used for the library may include bacteriophage, plasmid, cosmid, phagemid, etc. The DNA can be further amplified directly by the reverse transcriptase polymerase chain reaction (hereinafter briefly referred to as "RT-PCR" using mRNA fractions prepared from tissues and cells.

Examples of DNAs coding for the human BTC protein represented by SEQ ID NO. 1 are, for example, a DNA comprising a nucleotide sequence represented by SEQ ID NO. 7 (EP-A-0555785) and so on. Examples of DNAs coding for the mouse BTC protein represented by SEQ ID NO. 2 are, for example, a DNA comprising a nucleotide sequence represented by SEQ ID NO. 8 (Science, 259: 1604 (1993)) and so on.

The DNA coding for the BTC protein or a mutein thereof can be cloned by

- (1) carrying out the PCR amplification using a synthetic DNA primer having a partial nucleotide sequence of the DNA coding for the BTC protein or a mutein thereof; or
- (2) effecting the selection of a DNA constructed in a suitable vector, based on the hybridization with a labeled DNA fragment or a labeled synthetic DNA coding for a part or all of the BTC protein or a mutein thereof. The hybridization is carried out according to methods as disclosed in, for example, Molecular Cloning, 2nd Ed., J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989. When a DNA library commercially available in the market is used, the hybridization is carried out according to protocols manuals attached thereto. Specifically, the DNA coding for the BTC protein or a mutein thereof can be cloned according

to the method as described in EP-A-0482623, EP-A-0555785, Science, 259:1604 (1993) and so on, or the methods similar thereto.

5 The cloned BTC protein or a mutein thereof can be used as it is, or can be used, as desired, after modifications such as digestion with a restriction enzyme or addition of a linker or adapter, etc., depending upon objects. The DNA may have an initiation codon, ATG, on the 5' terminal side and a termination codon, TAA, TGA or TAG, on the 3'
10 terminal side. These initiation and termination codons can be ligated by using a suitable synthetic DNA adapter.

An expression vector for the BTC protein or a mutein thereof can be produced by, for example, (a) cutting out a target DNA fragment from the DNA coding for the BTC protein
15 or a mutein thereof and (b) ligating the target DNA fragment with the downstream site of a promoter in a suitable expression vector. Specifically, the expression vector for the BTC protein or a mutein thereof can be produced according to the method as described in EP-A-
20 0482623, EP-A-0555785, Science, 259:1604 (1993) and so on, or the methods similar thereto.

The composition for improving, the composition for promoting or the composition for preventing or treating undifferentiated type of pancreatic cancer of the present
25 invention can be produced in accordance with known methods of pharmaceutical making, using pharmaceutically acceptable carriers (including diluents and excipients) as desired.

For example, an aqueous solution for injection of the improving agent of the present invention can be produced by
30 ordinary means using solvents such as water (e.g., distilled water), aqueous solvents (e.g., physiological saline, Ringer's solution) and oily solvents (e.g., sesame oil, olive oil), as desired with additives such as dissolution aids (e.g., sodium salicylate, sodium acetate),
35 buffers (e.g., glucose, invert sugar), stabilizers (e.g., human serum albumin, polyethylene glycol), preservatives

(e.g., benzyl alcohol, phenol), and soothing agents (e.g., benzalkonium chloride, procaine hydrochloride).

The said aqueous solution for injection is adjusted to pH about 3 to 8, preferably pH about 5 to 7. To adjust liquid nature within the above pH range, dilute hydrochloric acid, dilute alkali (e.g., dilute sodium hydroxide, dilute sodium hydrogen carbonate) etc. may be added.

The BTC protein content in the composition for improving, the composition for promoting or the composition for preventing or treating of the present invention is normally about 1 to 95% by weight, preferably about 10 to 80% by weight, and more preferably about 20 to 70% by weight, relative to the entire preparation.

The activin content in the composition for improving, the composition for promoting or the composition for preventing or treating of the present invention is normally about 0 to 90% by weight, preferably about 0 to 80% by weight, relative to the entire preparation.

The content ratio of BTC protein and activin is normally about 1:10 to 10:1, preferably about 1:5 to 5:1, and more preferably about 1:2 to 2:1, with preference given to ratios of about 1:2.

The contents of other components (carrier etc.) can be chosen as appropriate, as long as the activity of BTC protein is not inhibited. They are normally about 0.01 to 90% by weight, preferably about 0.1 to 80% by weight, relative to the entire preparation.

In making the composition of the present invention, it is advantageous to further add human serum albumin (HSA) to the aqueous solution containing BTC protein to adjust its liquid nature to pH about 3 to 8, since BTC protein activity reduction during storage is suppressed.

Any HSA type can be used, and preferable examples of HSA are those having a quality for parenteral administration for clinical application of the composition of the

present invention. For example, HSA prepared by fractionally purifying plasma from a healthy human by Cohn's method 6 of ethanol fractionation can be used. Also, acetyltryptophan sodium or sodium caprylate may be
5 contained as a stabilizer. When prepared as an aqueous solution, HSA is preferably contained at about 0.1 to 50 mg, particularly 0.5 to 20 mg, per ml of aqueous solution.

In addition to the above-described HSA, the composition for improving, the composition for promoting or
10 the composition for preventing or treating of the present invention of the present invention may contain 1 or more substances selected from the group consisting of amino acids such as glycine, glutamic acid, aspartic acid, alanine and proline, monoamino aliphatic amino acids and
15 cyclic amino acids, monosaccharides such as glucose and mannose, sugar alcohols such as sorbitol and mannitol, and physiologically acceptable salts or derivatives thereof. When the composition prepared as an aqueous solution, the composition preferably contains about 10 to 100 mg of
20 monosaccharides or sugar alcohols and about 5 to 50 mg of amino acids per ml of aqueous solution.

When an acidic amino acid such as glutamic acid is added to adjust the solution nature of the preparation of the composition of the present invention, which contains
25 HSA to pH about 5 to 7, the desired liquid nature can be achieved by adding said substance at the above-specified amount. When no acidic amino acids are added as desired, mineral acids such as hydrochloric acid and phosphoric acid, or buffers such as succinic acid, tartaric acid and
30 citric acid, are used to achieve the desired liquid nature.

As the composition for improving of the present invention is of low toxicity, it can be used as a safe composition for improving pancreatic function against pancreatic dysfunction and hypofunction. Specifically, the
35 composition for improving of the present invention has an activity for promoting pancreatic beta cell differentiation

as a cell differentiation promoting factor. In other words, the composition for improving of the present invention is capable of acting on undifferentiated pancreatic stem cells to allow them to differentiate to pancreatic beta cells. The pancreatic beta cells thus produced via such inductive differentiation can secrete and produce insulin.

The composition for improving of the present invention also has an activity for induce differentiation of undifferentiated pancreatic stem cells to other pancreatic cells such as F cells which produce pancreatic peptides (hereinafter also referred to as PP). And, the composition for improving of the present invention has a glucose tolerance-improving activity in vivo. Therefore, the composition for improving of the present invention is therefore useful as a composition (prophylactic/therapeutic agent) improving for diabetes mellitus (e.g., insulin-dependent diabetes mellitus), pancreatic dysfunction in diabetes mellitus, pancreatic hypofunction associated with senile insulin secretion reduction etc.

Also, the composition for promoting of the present invention can also be used as a safe composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells, a composition for promoting an insulin secretion and so on.

As the composition for preventing or treating undifferentiated type of pancreatic cancer is of low toxicity, it can be used as a safe composition for preventing or treating undifferentiated type of pancreatic cancer.

Examples of subject animals of the composition of the present invention are human or mammals such as monkeys, hamadryad baboons, chimpanzees, pigs, bovines, sheep, horses, mice and rats.

The method of administration may be oral and or non-oral, non-oral administration is preferred. For example,

non-oral administration can be achieved by intravenous injection or subcutaneous injection.

Specific dose levels of the composition for improving or the composition for promoting may vary depending on
5 subject animal, severity of pancreatic dysfunction and other factors, the amount of the composition of the present invention used is normally about 0.02 μ g to 10 mg/kg, preferably about 2 μ g to 2 mg/kg, as a daily dose of BTC protein, for an adult, when used as an injectable
10 preparation.

Specific dose of the composition for preventing or treating undifferentiated type of pancreatic cancer may vary depending on subject animal, severity of
undifferentiated type of pancreatic cancer, the amount of
15 the composition of the present invention used is normally about 0.02 μ g to 10 mg/kg, preferably about 2 μ g to 2 mg/kg, as a daily dose of BTC protein, for an adult, when used as an injectable preparation.

The DNA-containing composition for improving, the DNA-
20 containing composition for promoting or the DNA-containing composition for preventing or treating undifferentiated type of pancreatic cancer of the present invention can be prepared by the same method as the above mentioned method for preparing the composition which comprises BTC protein
25 or a mutein thereof, said DNA alone or a suitable vector such as retrovirus vector, adenovirus vector, adenovirus-associated virus vector wherein said DNA is inserted.

As the DNA-containing composition for improving of the present invention is of low toxicity, it can be used as a
30 safe composition for improving pancreatic function against pancreatic dysfunction and hypofunction. Specifically, the DNA-containing composition for improving of the present invention has an activity for promoting pancreatic beta cell differentiation as a cell differentiation promoting
35 factor. In other words, the DNA-containing composition for improving of the present invention is capable of acting on

undifferentiated pancreatic stem cells to allow them to differentiate to pancreatic beta cells. The pancreatic beta cells thus produced via such inductive differentiation can secrete and produce insulin. The DNA-containing composition for improving of the present invention also has an activity for induce differentiation of undifferentiated pancreatic stem cells to other pancreatic cells such as F cells which produce PP And, the composition for improving of the present invention has a glucose tolerance-improving activity in vivo.

The DNA-containing composition for improving of the present invention is therefore useful as a composition (prophylactic/therapeutic agent) improving for diabetes mellitus (e.g., insulin-dependent diabetes mellitus), pancreatic dysfunction in diabetes mellitus, pancreatic hypofunction associated with senile insulin secretion reduction etc.

Also, the DNA-containing composition for promoting of the present invention can also be used as a safe composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells, a composition for promoting an insulin secretion and so on.

As the DNA-containing composition for preventing or treating undifferentiated type of pancreatic cancer is of low toxicity, it can be used as a safe composition for preventing or treating undifferentiated type of pancreatic cancer.

Examples of subject animals of the DNA-containing composition of the present invention are human or mammals such as monkeys, hamadryad baboons, chimpanzees, pigs, bovines, sheep, horses, mice and rats.

The method of administration may be oral or non-oral, non-oral administration is preferred. For example, non-oral administration can be achieved by intravenous injection or subcutaneous injection.

Specific dose levels of the DNA-containing composition for improving, the DNA-containing composition for promoting or the DNA-containing composition for preventing or treating undifferentiated type of pancreatic cancer of the present invention may vary depending upon a variety of factors including the object to be administered, the age, body weight, general health, sex, diet, time of administration, route of administration, and the severity of the symptom. In the case of oral administration, it is usually about 0.1 to 100 mg, preferably about 1.0 to 50 mg or, more preferably, about 1.0 to 20 mg per day for adults (as 60 kg). When it is administered parenterally, its dose at a time may vary depending upon the object to be administered, organs to be administered, symptoms, administering methods, etc. but, in the case of injections, it is usually convenient to give by an intravenous route in an amount of about 0.01 to 30 mg, preferably about 0.1 to 20 mg or, more preferably, about 0.1 to 10 mg per day to adults (as 60 kg). In the case of other animals, the dose calculated for 60 kg may be administered as well.

The composition for improving of the present invention, which comprises BTC protein, acts on undifferentiated pancreatic stem cells to promote their differentiation to insulin-producing pancreatic beta cells. It also has an activity for induction of differentiation of undifferentiated stem cells to other pancreatic cells such as F cells which produce pancreatic peptide-producing peptide. The composition for improving of the present invention is useful as a composition for preventing or treating diabetes mellitus (e.g., insulin-dependent diabetes mellitus), pancreatic dysfunction in diabetes mellitus etc. And, the composition for improving is also useful as a composition for preventing or treating undifferentiated type of pancreatic cancer.

Examples

The present invention is hereinafter described in more detail by means of the following examples and test examples, but the scope of the invention is not limited thereby.

Example 1

Injectable preparation containing human BTC protein

2.5 g of human BTC protein (SEQ ID NO. 1) was dissolved in 1 liter of distilled water and 1.1 g of human serum albumin (HSA) was added to and dissolved in the resulting solution. The solution was subjected to sterilizing filtration and dispensed 4 ml to each ampules (5 ml volume). After drying in a freeze drying machine, each ampule was sealed to yield an ampule for dissolution before use. To use the ampule, it is opened and the contents are dissolved in 2 ml of physiological saline to yield an injectable solution for subcutaneous, intravenous or intramuscular administration. This injectable preparation is used as a composition for improving, a composition for promoting or a composition for preventing or treating undifferentiated type of pancreatic cancer.

Example 2

Injectable preparation containing human BTC protein and activin A

2.5 g of human BTC protein (SEQ ID NO. 1) and 12.5 g of activin A were dissolved in 1 liter of distilled water and 1.0 g of human serum albumin (HSA) was added to and dissolved in the resulting solution. The solution was subjected to sterilizing filtration and dispensed 4 ml to each ampules (5 ml volume). After drying in a freeze drying machine, each ampule was sealed to yield an ampule for dissolution before use. To use the ampule, it is opened and the contents are dissolved in 2 ml of physiological saline to yield an injectable solution for

subcutaneous, intravenous or intramuscular administration. This injectable preparation is used as a composition for improving, a composition for promoting or a composition for preventing or treating undifferentiated type of pancreatic cancer.

Example 3

Injectable preparation containing DNA coding for human BTC protein

2.5 g of human BTC protein (SEQ ID NO. 1) was dissolved in 1 liter of distilled water and 1.1 g of human serum albumin (HSA) was added to and dissolved in the resulting solution. The solution was subjected to sterilizing filtration and dispensed 4 ml to each ampules (5 ml volume). After drying in a freeze drying machine, each ampule was sealed to yield an ampule for dissolution before use. To use the ampule, it is opened and the contents are dissolved in 2 ml of physiological saline to yield an injectable solution for subcutaneous, intravenous or intramuscular administration. This injectable preparation is used as a DNA composition for improving, a DNA composition for promoting or a DNA composition for preventing or treating undifferentiated type of pancreatic cancer.

25

Example 4

Injectable preparation containing human BTC protein

0.5 g of human BTC protein (SEQ ID NO. 1) was dissolved in 1 liter of distilled water and 2.0 g of human serum albumin (HSA) was added to and dissolved in the resulting solution. The solution was subjected to sterilizing filtration and dispensed 4 ml to each ampules (5 ml volume). After drying in a freeze drying machine, each ampule was sealed to yield an ampule for dissolution before use. To use the ampule, it is opened and the contents are dissolved in 2 ml of physiological saline to

yield an injectable solution for subcutaneous, intravenous or intramuscular administration. This injectable preparation is used as a composition for improving, a composition for promoting or a composition for preventing or treating undifferentiated type of pancreatic cancer.

Example 5

Injectable preparation containing human BTC protein and activin A

2.5 g of human BTC protein (SEQ ID NO. 1) and 5.0 g of activin A were dissolved in 1 liter of distilled water and 1.0 g of human serum albumin (HSA) was added to and dissolved in the resulting solution. The solution was subjected to sterilizing filtration and dispensed 4 ml to each ampules (5 ml volume). After drying in a freeze drying machine, each ampule was sealed to yield an ampule for dissolution before use. To use the ampule, it is opened and the contents are dissolved in 2 ml of physiological saline to yield an injectable solution for subcutaneous, intravenous or intramuscular administration. This injectable preparation is used as a composition for improving, a composition for promoting or a composition for preventing or treating undifferentiated type of pancreatic cancer.

25

Test Example 1

Effect of BTC protein on differentiation to insulin-producing beta cells and differentiation to pancreatic polypeptide-producing F cells

The cell line AR42J [Christophe, American Journal of Physiology, 266:G963 (1994)], derived from a pancreatic cancer induced by a chemical carcinogen, was sown over a glass cover slip at a concentration of 10^5 cells/ml in Dulbecco's modified Eagle MEM (Flow, USA) containing 20 mM Hepes/NaOH (pH 7.4), 5 mM NaHCO_3 , 10% fetal bovine serum and various concentrations of human BTC protein (SEQ ID

NO:1), and was cultured at 37°C in a carbon dioxide gas incubator (5% carbon dioxide gas, 95% air). Five days later, the cells were fixed with 3% para-formaldehyde and treated with 0.1% Triton X-100 (trade name) for 5 minutes, after which they were incubated with Blocking Ace (Morinaga Milk Industry Co., Ltd., Japan) and a primary antibody (anti-insulin antibody or anti-pancreatic polypeptide antibody) then a secondary antibody (indocarbocyanine-conjugated donkey anti-rabbit IgG antibody or indocarbocyanine-conjugated donkey anti-guinea pig IgG antibody). The cells were then microscopically examined using Axiophoto, produced by Carl Zeiss (NY, USA). As a result, as shown by ○ in Figure 1, the number of fluorescently dyed cells, i.e., cells which differentiated to insulin-producing beta cells, increased with dependency on BTC protein concentration; in the presence of 2×10^{-9} M BTC protein, up to about 4% cells became insulin-producing beta cells. It was also found that about 5% cells differentiate to pancreatic polypeptide (PP)-producing F cells.

Similar results were obtained from mRNA analysis using RT-PCR. Specifically, in the presence of BTC protein, AR42J cells differentiated so that insulin mRNA, PP mRNA, glucokinase mRNA and glucose transporter 2 mRNA were synthesized, but glucagon mRNA was not detected.

Test Example 2

Effects of various factors on differentiation to insulin-producing beta cells

Using the same conditions as those in Test Example 1, the effects of various factors on differentiation to beta cells were investigated. As seen from some results shown in Figure 2, 1×10^{-9} M epithelial growth factor (EGF), transforming growth factor α (TGF- α), fibroblast growth factor (FGF), insulin-like growth factor (IGF), gastrin, cholecystokinin, TGF- β and activin A all failed to induce

differentiation of AR42J cells to insulin-producing beta cells, but 1×10^{-9} M human BTC protein (SEQ ID NO. 1) induced differentiation of about 2.5% AR42J cells to insulin-producing beta cells. As shown in Figure 2, AR42J cells failed to differentiate to insulin-producing beta cells in the presence of 2×10^{-9} M activin A and 1×10^{-9} M EGF, 2×10^{-9} M activin A and 1×10^{-9} M TGF- α , but 10% of AR42J cells differentiated to insulin-producing beta cells in the presence of 2×10^{-9} M activin A and 1×10^{-9} M human BTC protein. The result shows that activin A enhanced the differentiation-inducing activity of BTC protein.

Test Example 3

Insulin secretion in AR42J cells which have differentiated to insulin-producing beta cells

Using the same method as that in Test Example 1, AR42J cells were sown over a dish of 6 cm diameter at a density of 1×10^5 cells/ml, and were cultured in the presence of 1×10^{-9} M human BTC protein (SEQ ID NO. 1) and 2×10^{-9} M activin A for 5 days. The cells were then washed with DMEM and incubated for 60 minutes in a Krebs-Ringer bicarbonate buffer containing 5.5 mM glucose in the presence of 10 μ M tolbutamide or 40 mM potassium ions. After that the culture broth was collected and assayed for insulin concentration using TR-IFMA (time-resolved immunofluorometric assay system) [Lovgren et al., in "Alternative Immunoassays," ed. by W.P. Collins, John Wiley & Sons Ltd., p. 203 (1985)]. The results shown in Figure 3 demonstrate that the differentiated AR42J cells secreted significant amounts of insulin in the culture broth, and that this secretion was promoted by high concentrations of potassium ions or tolbutamide.

Test Example 4

Glucose tolerance-improving activity of BTC protein in diabetic mice

A male ICR mouse at 8 weeks of age was subjected to partial pancreatic perfusion with alloxan (100 mg/kg body weight; while the superior mesenteric vein was clamped, alloxan was intravenously administered to selectively destroy beta cells in the pancreatic tail and conserve those in the pancreatic head) to yield a diabetic model mouse (Diabetes Frontier, 7:285-286, 1966, and ibid. 7:287-288, 1966). This diabetic mouse was given subcutaneous administration of human BTC protein (SEQ ID NO. 1) at 1 mg/kg body weight/day for 8 consecutive weeks, starting at 1 day after alloxan treatment. Before alloxan treatment and 2, 4 and 8 weeks after alloxan treatment, an intraperitoneal glucose tolerance test (ipGTT) (2 g glucose/kg body weight) was conducted to determine blood glucose levels before glucose loading and 1 and 2 hours after glucose loading, with periodical determination of body weight change. As a result, there was no difference between the BTC protein administration and non-administration groups in case of ipGTT before alloxan treatment (Figure 4) and 4 weeks after alloxan treatment (Figure 5). As shown in Figure 6, however, a markedly decreased blood glucose level was noted 1 hour after glucose loading in the BTC protein administration group (▲) compared with the BTC protein non-administration group (●) in case of ipGTT 8 weeks after alloxan treatment. The results shown in Figure 4 to 6 demonstrate that human BTC protein has a glucose tolerance-improving activity. There was no significant difference in mouse body weight between the administration and non-administration groups.

Test Example 5

Growth-inhibiting activity of BTC protein against pancreatic cancer cells

About 3×10^3 of clone 71 cells of AR42J cells were sown over a Falcon-sharle of 3 cm diameter (BectonDickinson, USA) in Dulbecco's modified Eagle MEM containing 2 nM human BTC protein (SEQ ID NO. 1) and 1% fetal bovine serum, and was cultured at 37°C in the present of 5% carbon dioxide gas to measure a increase of number of cells periodically by coulter counter. As a control, a increase of number of cells was measured at a condition of absence of human BTC protein. The obtained results were shown in Figure 5. The results shown in Figure 7 demonstrate that the growth of clone 71 cells in the human BTC protein-containing medium were inhibited clearly compared with that in the non-human BTC protein-containing medium.

(i) SEQUENCE CHARACTERISTICS

(B) TYPE: Amino acid

(ii) MOLECULE TYPE: Protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1

INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 80

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2

BNSDOCID: <WO 9717086A2 I >

29

Gly Arg Cys Arg Phe Val Val Asp Glu Gln Thr Pro Ser Cys Ile Cys
50 55 60
Glu Lys Gly Tyr Phe Gly Ala Arg Cys Glu Arg Val Asp Leu Phe Tyr
65 70 75 80

INFORMATION FOR SEQ ID NO: 3;

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 14

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3

His Phe Ser Arg Cys Pro Lys Gln Tyr Lys His Tyr Cys Ile
1 5 10

INFORMATION FOR SEQ ID NO: 4;

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 7

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4

Gly Arg Cys Arg Phe Val Val
1 5

INFORMATION FOR SEQ ID NO: 5;

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 6

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5

Glu Gln Thr Pro Ser Cys

1 5

INFORMATION FOR SEQ ID NO: 6;

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 11

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6

Gly Ala Arg Cys Glu Arg Val Asp Leu Phe Tyr

1 5 10

INFORMATION FOR SEQ ID NO: 7;

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 240

(B) TYPE: Nucleic acid

(C) STRANDEDNESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE

(C) IDENTIFICATION METHOD: S

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7

GATGGGAATT CCACCAGAAG TCCTGAAACT AATGGCCTCC TCTGTGGAGA CCCTGAGGAA 60
AACTGTGCAG CTACCACCAC ACAATCAAAG CGGAAAGGCC ACTTCTCTAG GTGCCCCAAG 120
CAATACAAGC ATTACTGCAT CAAAGGGAGA TGCCGCTTCG TGGTGGCCGA GCAGACGCCC 180
TCCTGTGTCT GTGATGAAGG CTACATTGGA GCAAGGTGTG AGAGAGTTGA CTTGTTTTAC 240

INFORMATION FOR SEQ ID NO: 8;

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 240

(B) TYPE: Nucleic acid

(C) STRANDEDNESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE

(C) IDENTIFICATION METHOD: S

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8

GATGGGAACA CAACCAGAAC ACCAGAAACC AATGGCTCTC TTTGTGGAGC TCCTGGGGAA 60
AACTGCACAG GTACCACCCC TAGACAGAAA GTGAAAACCC ACTTCTCTCG GTGCCCCAAG 120
CAGTACAAGC ATTACTGCAT CCATGGGAGA TGCCGCTTCG TGGTGGACGA GCAAACCTCCC 180
TCCTGCATCT GTGAGAAAGG CTACTTTGGG GCTCGGTGTG AGCGAGTGGA CCTGTTTTAC 240

CLAIMS

1. A composition for improving pancreatic function which comprises a betacellulin protein or a mutein thereof.

2. The composition according to claim 1, wherein the betacellulin protein is a protein having the amino acid sequence shown by at least one SEQ ID NO. selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

3. The composition according to claim 1, wherein the betacellulin protein is a protein having the amino acid sequence shown by SEQ ID NO:1 or a protein having the amino acid sequence shown by SEQ ID NO:2.

4. The composition according to claim 1, wherein the mutein of the betacellulin protein is a protein having (i) an amino acid sequence resulting from deletion of about 1 to 40 amino acids from the amino acid sequence shown by SEQ ID NO:1 or SEQ ID NO:2, (ii) an amino acid sequence resulting from replacement of about 1 to 40 amino acids in the amino acid sequence shown by SEQ ID NO:1 or SEQ ID NO:2 by other amino acid sequences, or (iii) an amino acid sequence resulting from addition of about 1 to 40 amino acids to the amino acid sequence shown by SEQ ID NO:1 or SEQ ID NO:2.

5. The composition according to claim 1, wherein the mutein of the betacellulin protein is a protein having an amino acid sequence resulting from deletion of 12 or 30 amino acids from the N-terminus of the amino acid sequence shown by SEQ ID NO:1.

6. The composition according to claims 1 to 5, which further contains an activin.

7. The composition according to claim 6, wherein the content ratio of the activin to the betacellulin protein or a mutein thereof is about 1:10 to 10:1.

8. The composition according to claims 1 to 7, which is a composition for preventing or treating diabetes mellitus.

9. The composition according to claims 1 to 7, which is a composition for preventing or treating pancreatic dysfunction in diabetes mellitus or pancreatic hypofunction associated with senile insulin secretion reduction.

10. A composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells, which comprises a betacellulin protein or a mutein thereof.

11. A composition for preventing or treating undifferentiated type of pancreatic cancer, which comprises a betacellulin protein or a mutein thereof.

12. A method for improving pancreatic function of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal.

13. A method for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal.

14. A method for preventing or treating undifferentiated type of pancreatic cancer of human or mammal, which comprises administering an effective amount of a betacellulin protein or a mutein thereof to human or mammal.


15. A use of a betacellulin protein or a mutein thereof for the manufacture of a composition for improving pancreatic function.

16. A use of a betacellulin protein or a mutein thereof for the manufacture of a composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells.

17. A use of a betacellulin protein or a mutein thereof for the manufacture of a composition for preventing or treating undifferentiated type of pancreatic cancer.


1/7

Figure 1




2/7

Figure 2




3/7

Figure 3




4/7

Figure 4




5/7

Figure 5




6/7

Figure 6



7/7

Figure 7





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18 // (A61K 38/18, 38:22)	A3	(11) International Publication Number: WO 97/17086 (43) International Publication Date: 15 May 1997 (15.05.97)
(21) International Application Number: PCT/JP96/03277 (22) International Filing Date: 8 November 1996 (08.11.96) (30) Priority Data: 7/291238 9 November 1995 (09.11.95) JP (71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventor; and (75) Inventor/Applicant (for US only): KOJIMA, Itaru [JP/JP]; 1-7- 301, Bunkyocho 1-chome, Maebashi-shi, Gunma 371 (JP). (74) Agents: ASAHINA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 19 June 1997 (19.06.97)
(54) Title: COMPOSITION FOR IMPROVING PANCREATIC FUNCTION (57) Abstract The present invention provides an excellent composition for improving pancreatic function, the composition for promoting differentiation of undifferentiated pancreatic stem cells to pancreatic beta cells and the composition for preventing or treating undifferentiated type of pancreatic cancer, which comprises a BTC protein or a mutein thereof. The composition of the present invention acts on undifferentiated pancreatic stem cells to promote their differentiation to insulin-producing pancreatic beta cells. It also has an activity for induction of differentiation of undifferentiated pancreatic stem cells to other pancreatic cells such as F cells which produce pancreatic peptides. The composition of the present invention is therefore capable of promoting mitigation and healing of diabetes mellitus (e.g., insulin-dependent diabetes mellitus), pancreatic dysfunction in diabetes mellitus etc., and improves pancreatic function. And, the composition of the present invention is also useful as a composition for preventing or treating undifferentiated type of pancreatic cancer.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/JP 96/03277

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/18 //(A61K38/18,38:22)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 555 785 A (TAKEDA CHEMICAL INDUSTRIES) 18 August 1993 cited in the application see the whole document	1-17
A	INTERNATIONAL JOURNAL OF ONCOLOGY 7 (4). 1995. 825-829, XP000670300 YOKOYAMA M ET AL: "Betacellulin, a member of the epidermal growth factor family, is overexpressed in human pancreatic cancer." see the whole document	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

16 April 1997

Date of mailing of the international search report

29.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT.

International Application No

PCT/JP 96/03277

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>JOURNAL OF CLINICAL INVESTIGATION 97 (7). 1996. 1647-1654, XP000670303 MASHIMA H ET AL: "Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin -secreting cells." see the whole document -----</p>	1-17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 96/03277

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12-14
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 12-14
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
information on patent family members

International Application No
PCT/JP 96/03277

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 555785 A	18-08-93	AT 145939 T DE 69306273 D DE 69306273 T JP 6087894 A CA 2089111 A	15-12-96 16-01-97 03-04-97 29-03-94 11-08-93

Form PCT/ISA/210 (patent family annex) (July 1992)